The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Related to this article
The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.
Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives NDA Resubmission for Rivoceranib Plus Camrelizumab in Frontline Unresectable or Metastatic HCC
2
Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers
3
FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer
4
The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer
5